Pyridone-fused azabicyclic- or cytisine derivatives, their preparation and their use in addiction therapy
申请人:——
公开号:US20030065173A1
公开(公告)日:2003-04-03
Pyridone-fused azabicyclic compounds of the formula
1
and their pharmaceutically acceptable salts and prodrugs, wherein R
1
, R
2
and R
3
are defined below, intermediates and methods for their preparation. Compositions and methods for using compounds of the formula I in the treatment of neurological and mental disorders related to a decrease in cholinergic function such as nicotine addiction, Huntington's Chorea, tardive dyskinesia, hyperkinesia, mania, dyslexia, schizophrenia , analgesia, attention deficit disorder (ADD), multi-infarct demetia, age related cognitive decline, epilepsy, neurological and mental disorders related to a decrease in cholinergic function, senile dementia of the Alzheimer's type, Parkinson's disease, attention deficit hyperactivity disorder (ADHD), anxiety, obesity, Tourette's Syndrome and ulcerative colitis.
公式1中的吡啶并咪唑化合物及其药学上可接受的盐和前药,其中R1、R2和R3的定义如下,以及它们的中间体和制备方法。公式I化合物在治疗与胆碱能功能降低有关的神经和精神障碍方面的组合物和方法,例如尼古丁成瘾、亨廷顿舞蹈病、迟发性运动障碍、多动症、躁狂症、阅读障碍、精神分裂症、镇痛、注意力缺陷障碍(ADD)、多发性梗塞性痴呆、与胆碱能功能降低有关的神经和精神障碍、阿尔茨海默病、帕金森病、注意力缺陷过动症(ADHD)、焦虑症、肥胖症、抽动症和溃疡性结肠炎的治疗中使用。